We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$364M
AUM Growth
-$61.7M
(-14%)
Cap. Flow
-$51.8M
Cap. Flow
% of AUM
-14.24%
Top 10 Holdings %
Top 10 Hldgs %
49.17%
Holding
67
New
17
Increased
9
Reduced
10
Closed
14
Top Buys
| 1 |
RAPT
RAPT Therapeutics
RAPT
|
+$13.3M |
| 2 |
Allogene Therapeutics
ALLO
|
+$7.84M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.72M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$5.31M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$4.28M |
Top Sells
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$9.65M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$8.69M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$7.95M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$6.63M |
| 5 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$6.59M |
Sector Composition
| 1 | Healthcare | 84.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $40.6M | 11.17% |
+300,000
| New | +$39.4M |
|
|
RAPT
2
DELISTED
RAPT Therapeutics
RAPT
| $18.1M | 4.98% |
+71,250
| New | +$13.3M |
|
3
Ascendis Pharma A/S
ASND
$17.1B
| $17.8M | 4.88% |
135,000
| – | – |
|
4
Fate Therapeutics
FATE
$324M
| $16.1M | 4.41% |
185,000
| – | – |
|
5
Xenon Pharmaceuticals
XENE
$6.6B
| $15.8M | 4.35% |
850,000
| – | – |
|
6
Arvinas
ARVN
$517M
| $15.8M | 4.34% |
205,000
| – | – |
|
7
Syndax Pharmaceuticals
SNDX
$2.02B
| $15M | 4.13% |
875,000
-300,000
| -26% | -$5.49M |
|
8
Kura Oncology
KURA
$964M
| $14.6M | 4.01% |
700,000
+100,000
| +17% | +$2.48M |
|
9
Cogent Biosciences
COGT
$6.68B
| $13M | 3.57% |
1,600,000
| – | – |
|
|
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
| $12.1M | 3.33% |
1,250,000
-700,000
| -36% | -$6.59M |
|
11
Iovance Biotherapeutics
IOVA
$2.23B
| $11.7M | 3.22% |
450,000
-50,000
| -10% | -$1.3M |
|
12
Biogen
BIIB
$30.4B
| $11.3M | 3.09% |
32,500
+12,500
| +63% | +$3.79M |
|
13
Celldex Therapeutics
CLDX
$2.77B
| $9.53M | 2.62% |
285,000
+35,000
| +14% | +$961K |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.08M | 2.22% |
50,000
| – | – |
|
|
15
Allogene Therapeutics
ALLO
$618M
| $7.17M | 1.97% |
+275,000
| New | +$7.84M |
|
16
TG Therapeutics
TGTX
$8.4B
| $6.98M | 1.92% |
180,000
-20,000
| -10% | -$785K |
|
17
Aldeyra Therapeutics
ALDX
$102M
| $6.8M | 1.87% |
600,000
-50,000
| -8% | -$601K |
|
|
VRNA
18
DELISTED
Verona Pharma
VRNA
| $6.54M | 1.8% |
1,000,000
+60,957
| +6% | +$423K |
|
19
Viridian Therapeutics
VRDN
$1.99B
| $6.4M | 1.76% |
350,000
+50,000
| +17% | +$856K |
|
|
STSA
20
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $6.38M | 1.75% |
904,225
| – | – |
|
21
VistaGen Therapeutics
VTGN
$9.4M
| $6.3M | 1.73% |
66,667
-71,456
| -52% | -$5.29M |
|
|
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
| $6.11M | 1.68% |
18,000
| – | – |
|
|
BCYC
23
Bicycle Therapeutics
BCYC
$294M
| $6.07M | 1.67% |
200,000
+50,000
| +33% | +$1.51M |
|
|
EPIX
24
DELISTED
ESSA Pharma
EPIX
| $5.93M | 1.63% |
207,500
+32,500
| +19% | +$945K |
|
|
25
Rocket Pharmaceuticals
RCKT
$376M
| $5.54M | 1.52% |
125,000
-200,000
| -62% | -$8.69M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2021 Portfolio in Review
As of Q2 2021, Ghost Tree Capital held 67 positions worth $364M, down 14% from $425M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital withdrew a net $51.8M in Q2 2021, closing 14 positions and reducing 10 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $9.65M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 77% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in RAPT Therapeutics worth $18.1M.
- Ghost Tree Capital's largest Q2 2021 buy was RAPT Therapeutics: 71,250 shares worth $18.1M.
- Ghost Tree Capital added most to Biogen in Q2 2021, an estimated $3.79M increase.
- Ghost Tree Capital's biggest Q2 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $8.69M.
- Ghost Tree Capital fully exited Apellis Pharmaceuticals in Q2 2021, selling an estimated $9.65M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $364M portfolio in Q2 2021.
- Ghost Tree Capital opened 17 new positions and closed 14 in Q2 2021.
- Ghost Tree Capital's portfolio value fell 14% quarter-over-quarter to $364M.
Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.